|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12...234567891011121314» |
- tanespimycin (BMS-722782) / BMS
Trial termination, Metastases: Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Mar 17, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial termination, Post-transplantation: Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation (clinicaltrials.gov) - Mar 17, 2013
P1, N=3, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Terminated Completed --> Terminated; Lack of Accrual
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change, Post-transplantation: Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation (clinicaltrials.gov) - Mar 17, 2013
P1, N=3, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Terminated; Lack of Accrual N=24 --> 3
- Trial termination: Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant (clinicaltrials.gov) - Mar 13, 2013
P3, N=240, Terminated, Sponsor: OHSU Knight Cancer Institute
N=24 --> 3 Active, not recruiting --> Terminated
- | alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
New P2 trial, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 13, 2013
P2, N=50, Recruiting, Sponsor: Kristie Blum
- tanespimycin (BMS-722782) / BMS
Trial termination, Metastases: Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 28, 2013
P1, N=45, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Completed --> Terminated
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 27, 2013
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Completed --> Terminated Recruiting --> Active, not recruiting
- cefepime hydrochloride / Generic mfg.
Trial completion: Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (clinicaltrials.gov) - Feb 26, 2013
P1, N=70, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 26, 2013
P3, N=206, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Metastases: Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 17, 2013
P1/2, N=47, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- melphalan / Generic mfg.
Trial completion: Melphalan in Patients With Neoplastic Meningitis (clinicaltrials.gov) - Feb 14, 2013
P1, N=6, Completed, Sponsor: Duke University
Recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (clinicaltrials.gov) - Feb 13, 2013
P1/2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Initiation date: Dec 2012 --> Jan 2014
- trimethoprim/sulfamethoxazole / Generic mfg.
Trial withdrawal: Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies (clinicaltrials.gov) - Feb 12, 2013
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2012 --> Jan 2014 Not yet recruiting --> Withdrawn
- trimethoprim/sulfamethoxazole / Generic mfg.
Enrollment change: Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies (clinicaltrials.gov) - Feb 12, 2013
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=684 --> 0
- Farydak (panobinostat) / Secura Bio
Enrollment change: Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2013
P1, N=11, Completed, Sponsor: City of Hope Medical Center
N=684 --> 0 N=36 --> 11
- Farydak (panobinostat) / Secura Bio
Trial completion: Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2013
P1, N=11, Completed, Sponsor: City of Hope Medical Center
N=36 --> 11 Active, not recruiting --> Completed
- vincristine / Generic mfg.
Enrollment change: Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors (clinicaltrials.gov) - Feb 10, 2013
P2, N=56, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed N=100 --> 56
- Zolinza (vorinostat) / Merck (MSD)
New P2 trial: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - Feb 10, 2013
P2, N=12, Recruiting, Sponsor: National Cancer Institute (NCI)
- vincristine / Generic mfg.
Trial completion: Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors (clinicaltrials.gov) - Feb 10, 2013
P2, N=56, Completed, Sponsor: Columbia University
N=100 --> 56 Recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: BMS-247550 in Treating Patients With Advanced Cancers (clinicaltrials.gov) - Feb 7, 2013
P1, N=54, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=16, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| denintuzumab mafodotin (SGN-CD19A) / Seagen
New P1 trial: A Safety Study of SGN-CD19A for Leukemia and Lymphoma (clinicaltrials.gov) - Feb 5, 2013
P1, N=175, Recruiting, Sponsor: Seattle Genetics, Inc.
- ||| denintuzumab mafodotin (SGN-CD19A) / Pfizer
New P1 trial: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Feb 5, 2013
P1, N=120, Recruiting, Sponsor: Seattle Genetics, Inc.
- Vesanoid (tretinoin) / Roche
Trial termination, IO biomarker: Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy (clinicaltrials.gov) - Feb 3, 2013
P1/2, N=5, Terminated, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Study drug became commercially available.
- Trial completion, Metastases: Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Jan 30, 2013
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Study drug became commercially available. Active, not recruiting --> Completed
- Genasense (oblimersen) / Genta
Trial termination, Combination therapy, Metastases: Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma (clinicaltrials.gov) - Jan 23, 2013
P1, N=15, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Administratively complete.
- vincristine / Generic mfg.
Trial initiation date: Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma (clinicaltrials.gov) - Jan 23, 2013
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Administratively complete. Initiation date: Aug 2001 --> Nov 2001
- Trial completion: CBV: Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Jan 22, 2013
P2, N=147, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Initiation date: Aug 2001 --> Nov 2001 Active, not recruiting --> Completed
- Trial termination: Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - Jan 15, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.
- peripheral blood stem cell transplantation / National Cancer Institute
Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Jan 15, 2013
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1/2 trial, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Jan 14, 2013
P1/2, N=69, Suspended, Sponsor: Stanford University
- ispinesib (SB-715992) / Cytokinetics
Trial termination, Metastases: SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 10, 2013
P1, N=31, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Completed --> Terminated; Administratively Complete.
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Jan 10, 2013
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively Complete. Not yet recruiting --> Recruiting
- vincristine / Generic mfg.
Enrollment change: Bryostatin and Vincristine in B-Cell Malignancies (clinicaltrials.gov) - Jan 9, 2013
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=25 --> 18
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Enrollment change, Combination therapy, Surgery, Metastases: Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 8, 2013
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
N=25 --> 18 N=24 --> 36
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Trial completion, Combination therapy, Surgery, Metastases: Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 8, 2013
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
N=24 --> 36 Terminated --> Completed
- Trial termination: Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 6, 2013
P2, N=6, Terminated, Sponsor: Eastern Cooperative Oncology Group
Terminated --> Completed Active, not recruiting --> Terminated; Slow accrual
- Enrollment change: Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 6, 2013
P2, N=6, Terminated, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Terminated; Slow accrual N=36 --> 6
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: DA-EPOCH-R: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Jan 2, 2013
P=N/A, N=12, Recruiting, Sponsor: Baylor College of Medicine
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, IO biomarker: Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (clinicaltrials.gov) - Dec 20, 2012
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
N=36 --> 6 Suspended --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Enrollment closed: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 18, 2012
P2, N=50, Active, not recruiting, Sponsor: University of Nebraska
Suspended --> Completed Recruiting --> Active, not recruiting
- ||| ontuxizumab (MORAb-004) / Eisai
New P1 trial: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Dec 10, 2012
P1, N=65, Recruiting, Sponsor: Morphotek
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant (clinicaltrials.gov) - Dec 9, 2012
P2, N=0, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; low accrual
- Kepivance (palifermin) / SOBI, Amgen
Trial completion, IO biomarker: Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change, Post-transplantation: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Nov 26, 2012
P2, N=100, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=50 --> 100
- Enrollment change: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Nov 20, 2012
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=50 --> 100 N=30 --> 10
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Nov 18, 2012
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
- lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) - Nov 14, 2012
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 10 Suspended --> Active, not recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial completion, Metastases: S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction (clinicaltrials.gov) - Oct 30, 2012
P1, N=78, Completed, Sponsor: Southwest Oncology Group
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant (clinicaltrials.gov) - Oct 15, 2012
P=N/A, N=115, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed N=90 --> 115